Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure
A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
- Subcutaneous Administration of NRG-1 is well tolerated by CHF patients
- Subcutaneous Administration of NRG-1 improves the cardiac function of CHF patients
- Assessment of relative bioavailability of NRG-1 by Subcutaneous Administration
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Beijing, Kina
- Beijing Chaoyang Hospital, Capital Medical University
-
Beijing, Kina
- Beijing Anzhen Hospital of Capital University of Medical Sciences
-
Beijing, Kina
- Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences
-
Beijing, Kina
- General Hospital of People's Liberation Army
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age: 18-75 years old, no limitation in gender;
- Left ventricular ejection fraction (LVEF) ≤ 40% (ECHO);
- Patients with chronic heart failure (NYHA class II or III);
- In the past one month, the clinical condition (including history, clinical symptoms and signs) was relatively stable;
- Patients on standard treatment of chronic heart failure at the target dose or maximum tolerance dose for over 1 month ,or unchanged dose in last 1 month;
- Understand and sign the informed consent form;
Exclusion Criteria:
- Atrial fibrillation;
- Subject underwent cardiac pacemaker treatment;
- Subject underwent metal graft treatment;
- Claustrophobia;
- Acute myocardial infarction, cardiac ischemia indicated by 6-minute walk test, hypertrophic cardiomyopathy, constrictive pericarditis, significant valve disease or congenital heart disease, severe pulmonary hypertension;
- Ischemic heart failure without the revascularization or undergone the revascularization within last 6 months;
- Subject underwent cardiac surgery or cerebrovascular events within the previous six months;
- Subjects who plan to have cardiac transplantation;
- Severe hepatic and renal insufficiency (serum creatinine>2.0 mg /dl, AST or ALT is five times higher than the upper limit of normal range);
- Subject needs mechanical ventilation;
- Systolic blood pressure < 90mmHg, or > 160mmHg;
- Chronic heart failure complicated with acute hemodynamic disturbance or acute decompensation within last 1 month;
- Mobitz Type II or III° atrial ventricular block,severe ventricular arrhythmia (polymorphic and frequent premature ventricular beats, frequent non-sustained ventricular tachycardia);
- Serum potassium<3.2mmol/L, or>5.5mmol/L;
- Female subject is pregnant or plan to become pregnant
- Childbearing-aged female subject who is unmarried or dose not bear child;
- Subject with life expectancy less than 6 months as assessed by investigators;
- Subject participated in any other clinical trial within the previous three months;
- Subject with previous history of tumor, or current tumor patient, or subject with pre-cancerous disease manifested by pathological examination (such as ductal carcinoma in situ or cervical epithelial dysplasia)
- Examinations (physical examination, X-ray examination, type-B ultrasonic detection or other methods) reveal that the subject has malignant mass, gland hyperplasia or adenoma with endocrine activity, or impact on heart, or endocrine function (such as pheochromocytoma, thyroid enlargement);
- The Investigator deemed for whatever reason that the subject is not likely to complete the study or comply with the study procedures (due to administration or any other reason).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: placebo
|
Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
|
|
Eksperimentel: rhNRG-1
recombinant human neuregulin-1
|
Subcutaneous Administration:0.6ug/kg/day for 10days
Subcutaneous Administration 1.2ug/kg/day for 10 days
Vein infusion:0.6ug/kg/day for 10 days
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
cardiac function measured by MRI
Tidsramme: 30 days
|
30 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
cardiac function
Tidsramme: baseline, 30 days, 90day and180 days
|
6-minute walk test, cardiac function classification(NYHA),life quality score.
|
baseline, 30 days, 90day and180 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Runlin Gao, Cardiovascular Institute and Fuwai Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ZS-01-302
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .